# Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

> **NCT06490627** · PHASE2 · RECRUITING · sponsor: **National Institute of Blood and Marrow Transplant (NIBMT), Pakistan** · enrollment: 54 (estimated)

## Conditions studied

- Fetal Hemoglobin
- Thalassemia Major
- Genetic Disease

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT06490627
- **Lead sponsor:** National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2025-04-22
- **Final completion:** 2026-04-22
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06490627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06490627, "Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06490627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*